Nicole C. Valco

San Francisco
  • 505 Montgomery Street
  • Suite 2000
  • San Francisco, CA 94111-6538
  • USA
Profile Experience

Nicole Valco, a partner in the Complex Commercial Litigation Practice, advises market-leading companies on range of disputes in federal and state courts.

Ms. Valco has experience successfully litigating high-stakes cases through trial to verdict. Her practice covers a broad range of business disputes, including:

  • Business torts
  • Consumer protection and unfair business practices
  • Contract
  • Fraud
  • Privacy
  • Trade secrets
  • Intellectual property

She has particular experience with clients in several industries, including technology, energy, pharmaceutical, retail, financial, and fitness industries. 

Ms. Valco is an active member of the firm’s Training and Career Enhancement Committee and serves on the Board of Governors of the Northern California chapter of the Association of Business Trial Lawyers.

Ms. Valco’s experience includes representing:

  • Medivation 
    • Against a university professor who concealed, then sold, a billion-dollar oncology molecule. Obtained unanimous breach of contract jury verdict for this biopharmaceutical company, and the defendant paid all damages plus costs. (S.F. Superior)
    • In defense of the University of California’s patent license lawsuit seeking additional royalties on sales of Medivation’s blockbuster oncology drug. (S.F. Superior)
  • Deloitte & Touche in a putative securities class action and five separate mass actions alleging that Deloitte “participated or materially aided” certain securities sales by Aequitas Capital Management, in violation of the Oregon Securities Laws. (D. Or.)
  • Canopy Growth, the largest legal cannabis producer in North America, in a trademark infringement suit brought by Cointreau in the Southern District of New York. (S.D.N.Y.)
  • Marvell Semiconductor in a six-week trade secrets theft jury trial. The jury returned a complete defense verdict, which The Daily Journal recognized as the Top Defense Verdict of the year. (S.J. Superior)
  • PG&E as defendant in a two-month criminal trial and hundreds of related civil lawsuits. Successfully reduced PG&E’s potential fine in the criminal case from US$1.14 billion to US$3 million. No individuals were indicted. (N.D. Cal.)
  • Apricus Biosciences against Laboratoires Majorelle in an antitrust, breach of contract, and fraud action over a patent license agreement. Obtained dismissal of all claims. (S.D.N.Y.)
  • Ovation Pharmaceuticals (now Lundbeck) in a merger-to-monopoly case in which the Federal Trade Commission sought divestiture and disgorgement of more than US$100 million. After trial, the district court entered judgment for Ovation on all claims. (D. Minn.) The district court’s decision was affirmed by the Eighth Circuit.
  • A pioneering gene editing company in arbitration over a patent licensing dispute. Obtained favorable resolution.
  • SS&C, a financial technology company, in the pursuit of trade secret misappropriation claims in Illinois and Connecticut state courts against former employees charged with disseminating trade secrets to a competitor.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.